GHRP-2 Adverse Events: What Studies Report

What the published GHRP-2 record contains

GHRP-2 (growth hormone-releasing peptide-2, pralmorelin) is a synthetic ghrelin-receptor agonist that appears in the indexed literature mostly as a diagnostic stimulus rather than as a chronically administered treatment. Researchers described a simple GHRP-2-based test for identifying growth hormone deficiency in adults (https://pubmed.ncbi.nlm.nih.gov/10770184/), and a later European group reported on a simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (https://pubmed.ncbi.nlm.nih.gov/17609397/). Both of those papers were built around test performance — whether the GH response separated deficient from non-deficient adults — rather than around prospectively collected adverse-event tables.

That matters for anyone reading about side effects: the structure of a study determines what safety information it can produce. A single-visit diagnostic test observes a patient for a short window; it does not generate the kind of repeated-dosing safety dataset that a phase III drug trial produces. This page reports what the verified papers stated, grouped by body system, and says plainly where no structured adverse-event data were present.

Study-by-study overview

Endocrine and Pituitary Effects: What Studies Report

The most consistently documented GHRP-2 effects are the hormonal ones the compound is used to produce. In older men and women, researchers reported sustained elevation of pulsatile growth hormone secretion together with raised IGF-I, IGFBP-3 and IGFBP-5 concentrations across a 30-day continuous subcutaneous infusion (https://pubmed.ncbi.nlm.nih.gov/15126555/). That finding is usually read as a pharmacological effect rather than an adverse event, but it is also the mechanism through which any downstream endocrine or metabolic consequence would arise, since IGF-I elevation is the shared pathway for both intended and unintended outcomes.

In critically ill patients, researchers described a paradoxical gender dissociation within the growth hormone/IGF-I axis during protracted critical illness (https://pubmed.ncbi.nlm.nih.gov/10634385/) — an observation that the hormonal response to secretagogue exposure was not uniform across patient subgroups. The practical reading is that response magnitude in one population does not transfer cleanly to another, which also limits how far any safety observation can be generalised.

GHRP-2's diagnostic role in pituitary disease is covered in a Japanese review of adult growth hormone deficiency resulting from brain injury (https://pubmed.ncbi.nlm.nih.gov/19110756/), which situated aGHD assessment within post-traumatic endocrine evaluation. Reviews of that kind describe the clinical place of a test rather than enumerate per-patient reactions.

Cortisol, ACTH and Adrenal Axis Observations: What Studies Report

GHRP-2 does not act only on the GH axis. Researchers evaluated the diagnostic utility of corticotropin-releasing hormone and GH-releasing peptide-2 stimulation tests for differentiating hypothalamic from pituitary adrenal insufficiency, and examined the underlying causes of those presentations (https://pubmed.ncbi.nlm.nih.gov/42732957/). That the peptide is used diagnostically to probe the pituitary-adrenal axis indicates a documented interaction with ACTH and cortisol regulation — which is why endocrine-axis questions appear in discussions of the compound at all.

Secondary adrenal insufficiency itself is documented in endocrine case literature from unrelated causes: a 2017 case report described secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma (https://pubmed.ncbi.nlm.nih.gov/28871578/). That report is context for how pituitary-adrenal dysfunction is identified and described in published medicine; it is not a GHRP-2 adverse-event report and was not presented as one.

Glucose, Appetite and Body Weight: What Studies Report

The longest single-patient exposure in this verified set concerns metabolic endpoints. Researchers reported that one year of intranasal GHRP-2 application improved body weight and hypoglycaemia in a severely emaciated anorexia nervosa patient (https://pubmed.ncbi.nlm.nih.gov/26401470/). A single case report cannot establish frequency, and the direction of the glucose finding in a severely undernourished patient does not describe what happens in metabolically normal adults.

Beyond that report, the verified papers summarised here did not provide tabulated glucose, insulin-sensitivity or appetite adverse-event data for GHRP-2. Where readers encounter claims about glucose effects, the relevant question is which population, which route and which duration were studied — the one-year intranasal case (https://pubmed.ncbi.nlm.nih.gov/26401470/) and the 30-day infusion study in older adults (https://pubmed.ncbi.nlm.nih.gov/15126555/) describe very different exposure situations.

Injection-Site, Cardiovascular and Neurological Reactions: What Studies Report

Stated plainly: within the verified papers used on this page, no structured incidence data for injection-site reactions, blood-pressure or heart-rate changes, flushing, headache or other short-term symptomatic complaints were presented at abstract level. The diagnostic studies of GHRP-2 in adult GH deficiency were constructed around diagnostic accuracy (https://pubmed.ncbi.nlm.nih.gov/10770184/, https://pubmed.ncbi.nlm.nih.gov/17609397/), and the 30-day infusion work reported hormonal trajectories in older men and women (https://pubmed.ncbi.nlm.nih.gov/15126555/). Absence of reported events in these sources is not the same as evidence that such events do not occur; it means the question was not answered by the records summarised here.

Longer Exposure: What Studies Report

Two sources carry duration information in their own right. Researchers maintained a continuous subcutaneous infusion over 30 days in older men and women and reported that the GH and IGF-axis elevation was sustained rather than attenuating (https://pubmed.ncbi.nlm.nih.gov/15126555/), which speaks to whether tachyphylaxis developed over that window. The anorexia nervosa case extended to one year by the intranasal route in a single patient (https://pubmed.ncbi.nlm.nih.gov/26401470/). Nothing in this verified set reported multi-year follow-up, cancer-incidence surveillance, or long-term cardiovascular outcomes for GHRP-2.

Self-Administration Outside Clinical Settings: What Studies Report

A 2026 Frontiers in Endocrinology review of the emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis reported a gap between clinical evidence and patient self-administration (https://pubmed.ncbi.nlm.nih.gov/42395176/), meaning that structured safety datasets covering repeated, non-clinical use were not available within that review's clinical evidence base. In other words, the published record that exists was generated in supervised diagnostic and research settings, and the review itself flagged that non-clinical use outruns it.

A separate 2026 narrative review in Sexual Medicine Reviews examined peptides in urology and sexual medicine across clinical effectiveness, dosing, indications and safety (https://pubmed.ncbi.nlm.nih.gov/42862021/), illustrating that safety discussion in the peptide literature is frequently narrative — a qualitative appraisal of a heterogeneous evidence base rather than pooled incidence rates from controlled trials.

How frequency data are (and are not) reported

Readers looking for percentages — how often a given reaction occurred — will not find them in the sources summarised here. The reasons are structural:

• Diagnostic use is brief. A stimulation test exposes a patient once, so chronic-exposure events cannot be captured (https://pubmed.ncbi.nlm.nih.gov/17609397/).
• Sample sizes are small. The longer-exposure work involved limited numbers, including a 30-day infusion study in older men and women (https://pubmed.ncbi.nlm.nih.gov/15126555/) and a single-patient one-year case report (https://pubmed.ncbi.nlm.nih.gov/26401470/).
• Populations differ sharply. Critically ill patients, severely underweight patients and older adults are not interchangeable groups, as the dissociated axis response during protracted critical illness illustrated (https://pubmed.ncbi.nlm.nih.gov/10634385/).
• Reviews acknowledge the shortfall. The GH-IGF1 peptide review stated the distance between clinical evidence and self-administration outright (https://pubmed.ncbi.nlm.nih.gov/42395176/).

Limits of this evidence base

Taken together, the verified record describes GHRP-2 primarily as a pituitary stimulation agent used in endocrine diagnosis (https://pubmed.ncbi.nlm.nih.gov/10770184/, https://pubmed.ncbi.nlm.nih.gov/42732957/), with limited longer-exposure data in specific clinical populations (https://pubmed.ncbi.nlm.nih.gov/15126555/). No conclusion about tolerability in healthy adults using the compound repeatedly and unsupervised can be drawn from these papers, and the review literature identified that exact gap (https://pubmed.ncbi.nlm.nih.gov/42395176/). Statements that cannot be sourced to a study are simply absent here rather than estimated.

This page is for educational purposes only and is not medical advice; consult a licensed physician regarding any health condition, medication or hormone-axis question. It summarises what published research reported and makes no assertion about safety, suitability or outcome for any individual.

References

• A simple test for growth hormone deficiency in adults (The Journal of Clinical Endocrinology and Metabolism, 2000)
• A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (European Journal of Endocrinology, 2007)
• Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women (The Journal of Clinical Endocrinology and Metabolism, 2004)
• One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient (Journal of Cachexia, Sarcopenia and Muscle, 2015)
• A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness (The Journal of Clinical Endocrinology and Metabolism, 2000)
• Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests (Endocrine Journal, 2026)
• Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD (Brain and Nerve, 2008)
• Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma (The Tokai Journal of Experimental and Clinical Medicine, 2017)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)
• Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review (Sexual Medicine Reviews, 2026)